Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317336 | 0.89 | PSEN1 (0.34) | LMNAALDH1A1HPGDNLRP3PYGL | |
| SCHEMBL23317659 | 0.89 | CA1 (0.37) | LMNAHPGDPYGLCYP2C9TSHR | |
| SCHEMBL23317573 | 0.88 | LMNA (0.45) | LMNAALDH1A1HPGDNLRP3TSHR | |
| SCHEMBL23317216 | 0.87 | POLB (0.43) | LMNAALDH1A1HPGDNLRP3PYGL | |
| SCHEMBL23317320 | 0.87 | PYGL (0.44) | LMNAALDH1A1HPGDNLRP3PYGL | |
| SCHEMBL23317582 | 0.86 | KMT2A (0.36) | HPGDPOLBKMT2A | |
| SCHEMBL23317704 | 0.85 | LMNA (0.40) | LMNAALDH1A1HPGDPYGLCYP2C9 | |
| SCHEMBL23317208 | 0.85 | ATM (0.43) | LMNAALDH1A1NLRP3CYP2C9POLB | |
| SCHEMBL23317560 | 0.85 | ALDH1A1 (0.35) | LMNAALDH1A1HPGDPYGLCYP2C9 | |
| SCHEMBL23317692 | 0.80 | TSHR (0.46) | LMNAALDH1A1HPGDNLRP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | LMNA 3757/4885ALDH1A1 3411/4885HPGD 1633/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | LMNA 3757/4885ALDH1A1 3411/4885HPGD 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.